Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: A randomized, multicenter, phase II trial

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 6, 2010, Pages 2781-2789

  Petersenn, Stephan ^a   Schopohl, J ^b   Barkan, A ^c   Mohideen, P ^d   Colao, A ^e   Abs, R ^f   Buchelt, A ^d   Ho, Y Y ^d   Hu, K ^d   Farrall, A J ^g   Melmed, S ^h   Biller, B M K ⁱ   Brue, Thierry ^j   Caron, Philippe ^j   Chanson, Phillipe ^j   Cuneo, Ross ^j   Díaz, Angel ^j   Ghigo, Ezio ^j   Gaillard, Rolf ^j   Halperin, Irene ^j   Kleinberg, David ^j   Rohmer, Vincent ^j   Romijn, J A ^j   Schlienger, Jean Louis ^j   Stewart, Paul ^j   Tabarin, Antoine ^j   Trainer, Peter J ^j   Van Der Lely, A J ^j   Vance, Mary Lee ^j   more..

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j Massachusetts General Hospital ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLIPIZIDE; GROWTH HORMONE; METFORMIN; OCTREOTIDE; PASIREOTIDE; SOMATOMEDIN C; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; SOMATOSTATIN;

ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPONATREMIA; HYPOPHYSIS TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL GLUCOSE TOLERANCE TEST; OSTEOARTHRITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; ADOLESCENT; BIOASSAY; BLOOD; DOUBLE BLIND PROCEDURE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ACROMEGALY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; SOMATOSTATIN; YOUNG ADULT;

EID: 77954484928     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2272     Document Type: Article

References (18)

1. Melmed S 2006 Medical progress: acromegaly. N Engl J Med 355:2558-2573
2. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152
3. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A 2005 Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737-740
4. Nomikos P, Buchfelder M, Fahlbusch R 2005 The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152:379-387
5. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A 2009 Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
6. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D 2005 Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465-4473
7. Colao A, Cappabianca P, Caron P, De ME, Farrall AJ, Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M, T'Sjoen G, Bouterfa H, Cuneo RC 2009 Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf) 70:757-768
8. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J 2007 A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66:859-868
9. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716 (Pubitemid 34552506)
10. van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW 2004 A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 89:638-645
11. Johns MW 1991 A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540-545
12. Grass P, Marbach P, Bruns C, Lancranjan I 1996 Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 45:27-30
13. Lamberts SW, Oosterom R, Neufeld M, del Pozo E 1985 The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60:1161-1165 (Pubitemid 15064776)
14. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G 2006 Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397-1403
15. Cozzi R, Attanasio R 2007 Octreotide for acromegaly. Expert Rev Endocrinol Metab 2:129-145
16. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G 2003 Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 59:492-499
17. Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LF, Lombardi G, Pivonello R 2009 Impact of somatostatin analogs vs. surgery on glucose metabolism in acromegaly: results of a 5 years observational, open, prospective study. J Clin Endocrinol Metab 94:528-537
18. Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J 2006 Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 155:73-78